EVDI (Trabectedin) Patent Expiration, LOE Window & CMS Spending

EVDI (Trabectedin) by Apotex: FDA Orange Book core substance LOE 2043-02-18, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $4,535 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorApotex
FDA Application & PathwayN220837 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2043-02-18
Last Listed Patent or Exclusivity Date2043-02-18
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($4,535 intro WAC)